久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

News of Note—VBI Vaccines, BiondVax and more

fiercepharmaSeptember 06, 2017

Tag: VBI , vaccines , BiondVax

> VBI Vaccines won FDA approval for its phase 3 program of hep B shot Sci-B-Vac. Enrollment is expected to start this year in the U.S., Europe and Canada. The vaccine is already licensed in Israel and 14 other countries. Release

> AMAL Therapeutics raised €8 million to advance its experimental colorectal cancer vaccine into human testing. Labiotech.eu story

> BiondVax, which is working on a universal flu vaccine candidate, voluntarily delisted from the Tel Aviv Stock Exchange. The company is still listed on Nasdaq. Release

Previous:Therapure Biopharma to divest CDMO business for $290m

Next:Gavi to save 20M lives, $350B with vaccine program by 2020

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service